OMEROS CORP Operating Lease Cost
OMEROS CORP (OMER) reported Operating Lease Cost of $1.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- OMEROS CORP operating lease, cost for the quarter ending 2026-06-30 was $1.49M, a 11.43% decline year-over-year.
- OMEROS CORP operating lease, cost for the quarter ending 2026-03-31 was $1.49M, a 11.43% decline year-over-year.
- OMEROS CORP operating lease, cost for the quarter ending 2025-12-31 was $1.48M, a 6.70% decline year-over-year.
- OMEROS CORP operating lease, cost for the quarter ending 2025-09-30 was $1.48M, a 8.01% decline year-over-year.
- OMEROS CORP operating lease, cost for fiscal 2025 was $6.16M, a 3.76% decline from fiscal 2024.
- OMEROS CORP operating lease, cost for fiscal 2024 was $6.40M, a 0.94% decline from fiscal 2023.
- OMEROS CORP operating lease, cost for fiscal 2023 was $6.46M, a 5.07% increase from fiscal 2022.
- OMEROS CORP operating lease, cost for fiscal 2022 was $6.15M, a 16.46% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.49M 10-Q · filed 2026-08-12 | $2.98M 10-Q · filed 2026-08-12 | $4.45M derived: sum of 3 quarters · filed 2026-08-12 | $5.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.49M 10-Q · filed 2026-05-13 | $2.96M derived: sum of 2 quarters · filed 2026-05-13 | $4.44M derived: sum of 3 quarters · filed 2026-05-13 | $6.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.96M derived: sum of 2 quarters · filed 2026-03-31 | $4.64M derived: sum of 3 quarters · filed 2026-08-12 | $6.16M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.48M 10-Q · filed 2025-11-13 | $3.16M derived: sum of 2 quarters · filed 2026-08-12 | $4.69M 10-Q · filed 2025-11-13 | $6.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-12 | $3.21M 10-Q · filed 2026-08-12 | $4.94M derived: sum of 3 quarters · filed 2026-08-12 | $6.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-13 | $3.26M derived: sum of 2 quarters · filed 2026-05-13 | $4.87M derived: sum of 3 quarters · filed 2026-05-13 | $6.48M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.19M derived: sum of 2 quarters · filed 2026-03-31 | $4.80M derived: sum of 3 quarters · filed 2026-03-31 | $6.40M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.61M 10-Q · filed 2025-11-13 | $3.22M derived: sum of 2 quarters · filed 2025-11-13 | $4.82M 10-Q · filed 2025-11-13 | $6.43M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-14 | $3.21M 10-Q · filed 2025-08-14 | $4.82M derived: sum of 3 quarters · filed 2025-08-14 | $6.43M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.61M 10-Q · filed 2025-05-15 | $3.22M derived: sum of 2 quarters · filed 2025-05-15 | $4.82M derived: sum of 3 quarters · filed 2025-05-15 | $6.44M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.21M derived: sum of 2 quarters · filed 2025-03-31 | $4.83M derived: sum of 3 quarters · filed 2025-03-31 | $6.46M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.60M 10-Q · filed 2024-11-13 | $3.22M derived: sum of 2 quarters · filed 2024-11-13 | $4.85M 10-Q · filed 2024-11-13 | $6.47M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-07 | $3.25M 10-Q · filed 2024-08-07 | $4.87M derived: sum of 3 quarters · filed 2024-08-07 | $6.53M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $1.63M 10-Q · filed 2024-05-15 | $3.26M derived: sum of 2 quarters · filed 2024-05-15 | $4.92M derived: sum of 3 quarters · filed 2024-05-15 | $6.58M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $3.28M derived: sum of 2 quarters · filed 2024-04-01 | $4.95M derived: sum of 3 quarters · filed 2024-04-01 | $6.15M 10-K · filed 2024-04-01 |
| 2022-09-30 | $1.66M 10-Q · filed 2023-11-09 | $3.32M derived: sum of 2 quarters · filed 2023-11-09 | $4.53M 10-Q · filed 2023-11-09 | $6.35M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.66M 10-Q · filed 2023-08-09 | $2.87M 10-Q · filed 2023-08-09 | $4.70M derived: sum of 3 quarters · filed 2023-08-09 | $6.66M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.20M 10-Q · filed 2023-05-09 | $3.03M derived: sum of 2 quarters · filed 2023-05-09 | $4.99M derived: sum of 3 quarters · filed 2023-05-09 | $6.98M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $3.80M derived: sum of 2 quarters · filed 2023-03-13 | $5.78M derived: sum of 3 quarters · filed 2023-03-13 | $7.36M 10-K · filed 2023-03-13 |
| 2021-09-30 | $1.96M 10-Q · filed 2022-11-09 | $3.94M derived: sum of 2 quarters · filed 2022-11-09 | $5.53M 10-Q · filed 2022-11-09 | $7.04M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.98M 10-Q · filed 2022-08-09 | $3.57M 10-Q · filed 2022-08-09 | $5.08M derived: sum of 3 quarters · filed 2022-08-09 | $6.56M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.58M 10-Q · filed 2022-05-10 | $3.10M derived: sum of 2 quarters · filed 2022-05-10 | $4.58M derived: sum of 3 quarters · filed 2022-05-10 | $6.13M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.00M derived: sum of 2 quarters · filed 2022-03-01 | $4.55M derived: sum of 3 quarters · filed 2022-03-01 | $6.05M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.48M 10-Q · filed 2021-11-09 | $3.03M derived: sum of 2 quarters · filed 2021-11-09 | $4.54M 10-Q · filed 2021-11-09 | $6.02M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.55M 10-Q · filed 2021-08-09 | $3.02M 10-Q · filed 2021-08-09 | $4.54M derived: sum of 3 quarters · filed 2021-08-09 | $5.60M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $1.51M 10-Q · filed 2021-05-10 | $2.99M derived: sum of 2 quarters · filed 2021-05-10 | $4.05M derived: sum of 3 quarters · filed 2021-05-10 | $5.08M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.54M derived: sum of 2 quarters · filed 2021-03-01 | $3.57M derived: sum of 3 quarters · filed 2021-03-01 | $4.60M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.09M derived: sum of 2 quarters · filed 2020-11-09 | $3.12M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.06M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $1.03M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |